- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: Actemra® | R-1569 | RG-1569 | RHPM-1 | RoActemra®
tocilizumab is an approved drug (FDA (2010), EMA (2009))
Compound class: Antibody
Comment: Tocilizumab is an anti-IL-6 receptor mAb, with immunosuppressive action  that is approved for chronic autoimmune indications.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
Qyuns Therapeutics have a potential tocilizumab biosimilar (QX003S) in Phase 1 evaluation for rheumatoid arthritis (trial registry number ChiCTR1900021808).
In early March 2020, China's National Health Commission issued guidance that allows use of tocilizumab to treat patients with serious COVID-19-induced lung damage. Tocilizumab is predicted to mitigate against the uncontrolled immune response that is triggered by SARS-CoV-2 infection in some patients and which leads to potentially life-threatening lung damage.
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
View more information in the IUPHAR Pharmacology Education Project: tocilizumab
1. Maini RN, Taylor PC, Szechinski J, Pavelka K, Bröll J, Balint G, Emery P, Raemen F, Petersen J, Smolen J et al.. (2006)
Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate.
Arthritis Rheum., 54 (9): 2817-29. [PMID:16947782]
2. Matsuyama M, Suzuki T, Tsuboi H, Ito S, Mamura M, Goto D, Matsumoto I, Tsutsumi A, Sumida T. (2007)
Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman's disease.
Intern. Med., 46 (11): 771-4. [PMID:17541233]
3. Mihara M, Kasutani K, Okazaki M, Nakamura A, Kawai S, Sugimoto M, Matsumoto Y, Ohsugi Y. (2005)
Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family.
Int. Immunopharmacol., 5 (12): 1731-40. [PMID:16102523]
4. Nishimoto N, Kishimoto T. (2008)
Humanized antihuman IL-6 receptor antibody, tocilizumab.
Handb Exp Pharmacol, (181): 151-60. [PMID:18071945]
5. Ohsugi Y, Kishimoto T. (2008)
The recombinant humanized anti-IL-6 receptor antibody tocilizumab, an innovative drug for the treatment of rheumatoid arthritis.
Expert Opin Biol Ther, 8 (5): 669-81. [PMID:18407769]
6. Paul-Pletzer K. (2006)
Tocilizumab: blockade of interleukin-6 signaling pathway as a therapeutic strategy for inflammatory disorders.
Drugs Today, 42 (9): 559-76. [PMID:17028666]
7. Unizony S, Kermani TA. (2018)
IL-6 Blockade and its Therapeutic Success in Giant Cell Arteritis.
J Neuroophthalmol, 38 (4): 551-558. [PMID:30199509]
8. Yokota S, Miyamae T, Imagawa T, Katakura S, Kurosawa R, Mori M. (2005)
Clinical study of tocilizumab in children with systemic-onset juvenile idiopathic arthritis.
Clin Rev Allergy Immunol, 28 (3): 231-8. [PMID:16129907]